Keros Therapeutics (KROS) Net Cash Flow Growth (5y) (2024 - 2025)

Keros Therapeutics (KROS) Net Cash Flow Growth (5y) (2024 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,681.27 Bn 66,680.98 Bn -
2 Nanobiotix 1,911.83 Bn 1,911.77 Bn -
3 Akari Therapeutics 959.56 Bn 959.56 Bn -
4 BeOne Medicines 472.75 Bn 467.96 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.14 Bn 114.89 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.09 Bn 61.34 Bn 3.31 Bn
7 Belite Bio 62.34 Bn 62.34 Bn -
8 Argenx Se 55.94 Bn 50.76 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.52 Bn 34.51 Bn 959.66 Mn
10 Keros Therapeutics 383.94 Mn 96.54 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 -38.38%
Sep 30, 2025 18.12%
Jun 30, 2025 -18.50%
Mar 31, 2025 27.59%
Dec 31, 2024 48.85%
Sep 30, 2024 112.43%
Jun 30, 2024 -47.73%
Mar 31, 2024 115.32%